

Table 1 Patient demographics and adherence

		2016 (n=98)	2017 (n=100)	2018 (n=100)	Total (n=298)
Demographics	Male	60 (61.2%)	60 (60.0%)	70 (70.0%)	190 (63.8%)
	Mean age (years) [range]	4.5 [2-14]	4.6 [2-13]	4.0 [2-11]	4.4 [2-14]
Severity	Severe/Life threatening	70 (71.4%)	69 (69.0%)	72 (72.0%)	211 (70.8%)
OCS prescribed	Adherence to protocol*	88 (89.8%)	80 (80.0%)	90 (90.0%)	260 (87.2%)
	Received prednisolone**	90 (91.8%)	9 (9%)	2 (2%)	99 (33.2%)
	Mean dose (SD, range) (mg/kg)	1.34 (SD 0.39, 0.17-2.11)	1.07 (SD 0.41, 0.63-0.75)	1.76 (SD 0.52, 1.40-2.13)	1.32 (SD 0.40, 0.17-2.13)
	Received dexamethasone	10 (10.2%)	91 (91.0%)	98 (98.0%)	197 (66.1%)
	Mean dose (SD, range) (mcg/kg)	330 (SD 0.09, 280-580)	540 (SD 0.10, 260-670)	300 (SD 0.06, 140-600)	410 (SD 0.14, 140-670)
	Episodic viral wheeze	46 (46.9%)	55 (55.0%)	69 (69.0%)	170 (57.0%)
Diagnosis	Exacerbation of asthma	44 (44.9%)	31 (31.0%)	20 (20.0%)	95 (31.9%)
	Lower respiratory tract infection	8 (8.2%)	13 (13.0%)	11 (11.0%)	32 (10.7%)
	Other***	0 (0.0%)	1 (1.0%)	0 (0.0%)	1 (0.3%)

Note: \*For 2016, adherence to protocol was determined as patients receiving prednisolone only. For 2017 and 2018, adherence to protocol was determined as receiving recommended

dose of dexamethasone +/- 10% or receiving the maximum allowed total dose (16mg). \*\*In the 2016, 2 patients received both prednisolone and dexamethasone, with prednisolone being given first. \*\*\*One case of persistent bacterial bronchitis with wheeze as a predominant feature was designated "other".